Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical device company MAKO Surgical
With that in mind, let's take a closer look at MAKO's business and see what CAPS investors are saying about the stock right now.
|Headquarters (Founded)||Fort Lauderdale, Fla. (2004)|
|Market Cap||$1.6 billion|
|Trailing-12-Month Revenue||$58.4 million|
Chairman/CEO Maurice Ferre
CFO Fritz LaPorte
|Return on Equity (Average, Past 3 Years)||(58.4%)|
|Cash/Debt||$59.7 million / $0|
Smith & Nephew
Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.
On CAPS, 96% of the 453 members who have rated MAKO believe the stock will outperform the S&P 500 going forward. These bulls include All-Stars TMFHelical and HealthcareGuy, both of whom are ranked in the top 5% of our community.
Over the next five years, in fact, MAKO is expected to grow its bottom line at a brisk rate of 20% annually. That's much faster than listed rivals Smith & Nephew (10%), Stryker (11%), and Zimmer (10%).
Hip replacement is a $6B market, where traditional procedures lack the precision of MAKOplasty, and as a result do not last as long and have inferior users experiences. ... MAKO in my estimation is still a multi bagger from here and will most likely not remain public too much longer, as large cap med tech companies have a much larger appetite for M&A than their more talked about big pharma counterparts (who can always hedge themselves by doing sales partnerships instead).
...[F]undamentally I still view this stock as cheap, given the scarcity value of the product and market opportunity, and the fast approaching launch of the new Hip application.
What do you think about MAKO, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!
Interested in another easy way to track MAKO? Add it to your watchlist.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of MAKO, Smith & Nephew, and Stryker. The Fool owns shares of Zimmer. Try any of our Foolish newsletter services free for 30 days.